T2∗ imaging of the heart: Methods, applications, and outcomes

Topics in Magnetic Resonance Imaging

Volumn 23, Issue 1, 2014, Pages 13-20

  Baksi, Arun John ^a   Pennell, Dudley John ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Cardiac iron; T2 imaging; Thalassemia

Indexed keywords

IRON; BIOLOGICAL MARKER;

ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; BREATH HOLDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MAGNETIC RESONANCE; HUMAN; IRON OVERLOAD; MAGNETIC FIELD; OUTCOME ASSESSMENT; PRIORITY JOURNAL; ALGORITHM; COMPUTER ASSISTED DIAGNOSIS; HEART FAILURE; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; REVIEW;

ALGORITHMS; BIOLOGICAL MARKERS; HEART FAILURE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IRON; IRON OVERLOAD; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY;

EID: 84907938585     PISSN: 08993459     EISSN: 15361004     Source Type: Journal    
DOI: 10.1097/RMR.0000000000000011     Document Type: Article

References (39)

1. Modell B, Khan M, Darlison M. Survival in beta thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000;355:2051-2052.
2. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and diseas complications in thalassemia major. Ann N Y Acad Sci. 1998;850: 227-231.
3. Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342:1077-1084.
4. ∗ (T2 star) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171-2179.
5. Pennell DJ, Udelson JE, Arai AE, et al. Cardiovascular function and treatment in A-thalassemia major. A consensus statement from the American Heart Association. Circulation. 2013;128:281-308
6. ∗ technique for the quantification of tissue iron. Haematologica. 2006;91:1388-1391.
7. ∗ measurements of myocardial iron in thalassaemia. Int J Cardiovasc Imaging. 2005;21:531-538.
8. ∗-based MR imaging and its special applications. RadioGraphics. 2009;29:1433-1449.
9. Brasch RC, Wesbey GE, Gooding CA, et al. Magnetic resonance imaging of transfusional hemosiderosis complicating thalassemia major. Radiology. 1984;150:767-771.
10. Stark DD, Moseley ME, Bacon BR, et al. Magnetic resonance imaging and spectroscopy of hepatic iron overload. Radiology. 1985;154:137-142.
11. Johnston DL, Rice L, Vick GW 3rd, et al. Assessment of tissue iron overload by nuclear magnetic resonance imaging. Am J Med. 1989;87:40-47.
12. Jensen PD, Jensen FT, Christensen T, et al. Non-invasive assessment o tissue iron overload in the liver by magnetic resonance imaging. Br J Haematol. 1994;87:171-184.
13. Kaltwasser JP, Gottschalk R, Schalk KP, et al. Non-invasive quantitation of liver iron-overload by magnetic resonance imaging. Br J Haematol. 1990;74:360-363.
14. St Pierre TG, Clark PR, Chua-anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005;105:855-861
15. Cohen AR, Galanello R, Pennell DJ, et al. Thalassaemia. Hematology (Am Soc Hematol Educ Prog). 2004;14-34.
16. Angelucci E, Giovagnoni A, Valeri G, et al. Limitations of magnetic resonance imaging in measurement of hepatic iron. Blood. 1997;90:4736-4742.
17. Jensen PD, Jensen FT, Christensen T, et al. Indirect evidence for the potential ability of magnetic resonance imaging to evaluate the myocardial iron content in patients with transfusional iron overload. Magma. 2001;12:153-166.
18. He T, Gatehouse PD, Anderson LJ, et al. Development of a novel optimized breathhold technique for myocardial T2 measurement in thalassemia. J Magn Reson Imaging. 2006;24:580-585.
19. Guo H, Au WY, Cheung JS, et al. Myocardial T2 quantitation in patients with iron overload at 3 tesla. J Magn Reson Imaging. 2009;30:394-400.
20. Kim D, Jensen JH, Wu EX, et al. Breathhold multiecho fast spin-echo pulse sequence for accurate R2 measurement in the heart and liver. Magn Reson Med. 2009;62:300-306.
21. Jensen JH, Tang H, Tosti CL, et al. Separate MRI quantification of dispersed (ferritin-like) and aggregated (hemosiderin-like) storage iron. Magn Reson Med. 2010;63:1201-1209.
22. ∗ cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging. 2003;18:33-39.
23. ∗ technique for myocardial iron measurement in thalassemia. J Magn Reson Imaging. 2007;25:1205-1209.
24. ∗ measurements in iron-overloaded thalassemia: an in vivo study to investigate optimal methods of quantification. Magn Reson Med. 2008;60:1082-1089.
25. ∗ magnetic resonance and cardiac iron. Circulation. 2011;123:1519-1528.
26. ∗ cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging. 2003;18:33-39.
27. ∗ imaging of transfusional iron burden at 3T and comparison with 1.5T. J Magn Reson Imaging. 2007;25:540-547.
28. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;86:417-496.
29. Carpenter JP, Grasso AE, Porter JB, et al. On myocardial siderosis and left ventricular dysfunction in hemochromatosis. J Cardiovasc Magn Reson. 2013;15:24.
30. Westwood MA, Anderson LJ, Maceira AM, et al. Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron. J Magn Reson Imaging. 2007;25:1147-1151.
31. ∗ magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120:1961-1968.
32. ∗ cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10:42.
33. ∗ cardiovascular magnetic resonance in A-thalassemia major. Haematologica. 2013;98:1368-1374.
34. ∗ to right ventricular function in thalassaemia major. Eur Heart J. 2010;31:1648-1654.
35. ∗ cardiovascular magnetic resonance. Br J Haematol. 2004;127:348-355.
36. Tanner MA, Galanello R, Dessi C, et al. Combined chelation therapy in thalassaemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson. 2008;10:12.
37. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107:3738-3744.
38. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115:1876-1884.
39. Pennell DJ, Porter JB, Piga A, et al. A multicenter, randomized, open-label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with A-thalassemia major and iron overload (CORDELIA). Blood (ASH Annual Meeting Abstracts). 2012;120:abstract 2124.